If you’ve been treated for hormone-receptor positive early breast cancer and have completed five years of hormone (endocrine) therapy — such as tamoxifen or an aromatase inhibitor (AI) — you may have heard about continuing treatment longer. A large international study published in The Lancet (2025) examined whether staying on … More Extending Endocrine Therapy Beyond 5-Years After Breast Cancer: Balancing Long-Term Benefit and Quality of Life